<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>
  • Using technology in tumor genomics to develop precision cancer therapeutics

    Investor Relations

Investor Relations

Welcome to Trovagene Investor Relations

Corporate Profile

We are a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging our proprietary Precision Cancer Monitoring® (PCM) technology and experience in tumor genomics.  Our broad intellectual property and proprietary technology allow us to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting patient response to cancer therapies.  We offer our PCM technology at our CLIA/CAP-accredited laboratory and plan to continue to vertically integrate our PCM technology with the development of precision cancer therapeutics.  We believe our ctDNA PCM technology and expertise in liquid biopsy testing provides a unique advantage for the development of precision cancer therapeutics.

Company Overview - June 2017
Recent News
Aug 16, 2017

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced positive data from a preclinical in-vivo study examining the combination of their PLK1 inhibitor,...

Aug 9, 2017

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced company highlights and financial results for the second quarter ended June 30, 2017. The company does...

Jul 28, 2017

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that Trovagene, and Antonius Schuh and Stephen Zaniboni, the company's former Chief Executive Officer...

More >

Stock Information
NASDAQTROV
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@trovagene.com

Contact

Events
June 15, 2017
12:00pm - 12:30pm PDT

Bill Welch, CEO of Trovagene, will be presenting at the Marcum 2017 MicroCap Conference on June 15, 2017 at 3:00 PM EDT at the Grand Hyatt Hotel in Julliard on the conference level. The...

June 7, 2017
11:30am - 12:00pm PDT

Trovagene CEO, Bill Welch, will be presenting at the 7th Annual LD Micro Invitational Conference June 7, 2017 at 11:30 AM PDT at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. The...

May 10, 2017
5:00pm - 6:00pm EDT

Trovagene's senior management team will host a conference call on Wednesday, MAy 10th, 2017, at 5:00 pm EDT (2:00 pm PDT) to discuss results and update investors on the Company's progress.

3:34
3:34
Wistia video thumbnail - Susann-Berz Patient Video- Home Page

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?

Cancel
message